A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

Stephen Couban; Giulia Benevolo; William Donnellan; Jennifer Cultrera; Steffen Koschmieder; Srdan Verstovsek; Gregory Hooper; Christian Hertig; Maneesh Tandon; Natalie Dimier; Vikram Malhi; Francesco Passamonti

doi:10.1186/s13045-018-0661-x

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

Stephen Couban, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, Gregory Hooper, Christian Hertig, Maneesh Tandon, Natalie Dimier, Vikram Malhi, Francesco Passamonti

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Original language	English
Article number	122
Journal	Journal of Hematology and Oncology
Volume	11
Issue number	1
DOIs	https://doi.org/10.1186/s13045-018-0661-x
Publication status	Published - Sept 24 2018
Externally published	Yes

ASJC Scopus Subject Areas

Molecular Biology
Hematology
Oncology
Cancer Research

Keywords

Hedgehog pathway inhibitor
Hematologic malignances
Hematopoiesis
Myelofibrosis
Ruxolitinib
Vismodegib

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s13045-018-0661-x

Cite this

Couban, S., Benevolo, G., Donnellan, W., Cultrera, J., Koschmieder, S., Verstovsek, S., Hooper, G., Hertig, C., Tandon, M., Dimier, N., Malhi, V., & Passamonti, F. (2018). A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis. Journal of Hematology and Oncology, 11(1), Article 122. https://doi.org/10.1186/s13045-018-0661-x

Couban, S, Benevolo, G, Donnellan, W, Cultrera, J, Koschmieder, S, Verstovsek, S, Hooper, G, Hertig, C, Tandon, M, Dimier, N, Malhi, V & Passamonti, F 2018, 'A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis', Journal of Hematology and Oncology, vol. 11, no. 1, 122. https://doi.org/10.1186/s13045-018-0661-x

@article{4f624404674347f7bb69f832afa82dd7,

title = "A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis",

keywords = "Hedgehog pathway inhibitor, Hematologic malignances, Hematopoiesis, Myelofibrosis, Ruxolitinib, Vismodegib",

author = "Stephen Couban and Giulia Benevolo and William Donnellan and Jennifer Cultrera and Steffen Koschmieder and Srdan Verstovsek and Gregory Hooper and Christian Hertig and Maneesh Tandon and Natalie Dimier and Vikram Malhi and Francesco Passamonti",

note = "Publisher Copyright: {\textcopyright} 2018 The Author(s).",

year = "2018",

month = sep,

day = "24",

doi = "10.1186/s13045-018-0661-x",

language = "English",

volume = "11",

journal = "Journal of Hematology and Oncology",

issn = "1756-8722",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

AU - Couban, Stephen

AU - Benevolo, Giulia

AU - Donnellan, William

AU - Cultrera, Jennifer

AU - Koschmieder, Steffen

AU - Verstovsek, Srdan

AU - Hooper, Gregory

AU - Hertig, Christian

AU - Tandon, Maneesh

AU - Dimier, Natalie

AU - Malhi, Vikram

AU - Passamonti, Francesco

PY - 2018/9/24

Y1 - 2018/9/24

KW - Hedgehog pathway inhibitor

KW - Hematologic malignances

KW - Hematopoiesis

KW - Myelofibrosis

KW - Ruxolitinib

KW - Vismodegib

UR - http://www.scopus.com/inward/record.url?scp=85053820642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053820642&partnerID=8YFLogxK

U2 - 10.1186/s13045-018-0661-x

DO - 10.1186/s13045-018-0661-x

M3 - Article

C2 - 30249277

AN - SCOPUS:85053820642

SN - 1756-8722

VL - 11

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

IS - 1

M1 - 122

ER -

A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis

ASJC Scopus Subject Areas

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this